Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDITAS MEDICINE, INC.

(EDIT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Easing Slightly From Intra-Day Highs Near Close

09/29/2021 | 03:56pm EST


© MT Newswires 2021
All news about EDITAS MEDICINE, INC.
11/12Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for..
GL
11/12Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for..
CI
11/09EDITAS MEDICINE, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
11/08Health Care Stocks Adding Support Shortly Before Monday Close
MT
11/08Health Care Stocks Edging Higher in Monday Trading
MT
11/08Editas Medicine Swings to Q3 Loss as Revenue Declines; Beats Street Forecast
MT
11/08Editas Medicine Announces Third Quarter 2021 Results and Business Updates - Form 8-K
PU
11/08EDITAS : Q3 Earnings Snapshot
AQ
11/08Editas Medicine Announces Third Quarter 2021 Results and Business Updates
GL
11/04Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Edit..
GL
More news
Analyst Recommendations on EDITAS MEDICINE, INC.
More recommendations
Financials (USD)
Sales 2021 17,4 M - -
Net income 2021 -206 M - -
Net cash 2021 412 M - -
P/E ratio 2021 -8,97x
Yield 2021 -
Capitalization 1 875 M 1 875 M -
EV / Sales 2021 84,1x
EV / Sales 2022 65,6x
Nbr of Employees 235
Free-Float 99,6%
Chart EDITAS MEDICINE, INC.
Duration : Period :
Editas Medicine, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDITAS MEDICINE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 27,72 $
Average target price 52,07 $
Spread / Average Target 87,8%
EPS Revisions
Managers and Directors
James C. Mullen Chairman, President & Chief Executive Officer
Michelle Robertson Treasurer, Chief Financial & Accounting Officer
Lisa A. Michaels Chief Medical Officer & Executive Vice President
Noaman Akhtar Senior Director-Clinical Operations
David Litvak Director-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
EDITAS MEDICINE, INC.-60.46%1 875
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298